NO20004502D0 - Nye sammensetninger av eprosartan - Google Patents

Nye sammensetninger av eprosartan

Info

Publication number
NO20004502D0
NO20004502D0 NO20004502A NO20004502A NO20004502D0 NO 20004502 D0 NO20004502 D0 NO 20004502D0 NO 20004502 A NO20004502 A NO 20004502A NO 20004502 A NO20004502 A NO 20004502A NO 20004502 D0 NO20004502 D0 NO 20004502D0
Authority
NO
Norway
Prior art keywords
eprosartan
new compositions
composition
solvate
hydrate
Prior art date
Application number
NO20004502A
Other languages
English (en)
Other versions
NO20004502L (no
NO331207B1 (no
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20004502D0 publication Critical patent/NO20004502D0/no
Publication of NO20004502L publication Critical patent/NO20004502L/no
Publication of NO331207B1 publication Critical patent/NO331207B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20004502A 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav NO331207B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (3)

Publication Number Publication Date
NO20004502D0 true NO20004502D0 (no) 2000-09-08
NO20004502L NO20004502L (no) 2000-11-07
NO331207B1 NO331207B1 (no) 2011-10-31

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004502A NO331207B1 (no) 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Country Status (21)

Country Link
EP (1) EP1061803B1 (no)
JP (1) JP2002506010A (no)
KR (1) KR20010041796A (no)
CN (1) CN1299235A (no)
AT (1) ATE508633T1 (no)
AU (1) AU757547B2 (no)
BR (1) BR9908691A (no)
CA (1) CA2323363C (no)
CY (1) CY1111738T1 (no)
CZ (1) CZ303067B6 (no)
DK (1) DK1061803T3 (no)
ES (1) ES2366394T3 (no)
HU (1) HU228574B1 (no)
IL (1) IL138345A (no)
NO (1) NO331207B1 (no)
NZ (1) NZ506700A (no)
PL (1) PL192545B1 (no)
SI (1) SI1061803T1 (no)
TR (1) TR200002646T2 (no)
WO (1) WO1999045779A1 (no)
ZA (1) ZA991922B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484247B2 (ja) 1995-02-24 2010-06-16 エラン ファーマ インターナショナル,リミティド ナノ粒子分散体を含有するエアロゾル
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
HUP0301335A3 (en) * 2000-04-12 2006-02-28 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004064834A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
CN1972679B (zh) * 2004-06-23 2010-07-28 索尔瓦药物有限公司 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
WO2009013760A2 (en) * 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
BR9708336A (pt) * 1996-03-29 1999-08-03 Smithkline Beecham Corp Diidrato de eprosartan e processo para sua produção e formulação
DK1027047T3 (da) * 1997-08-06 2007-01-29 Smithkline Beecham Corp Eprosartan-arginyl-ladningsneutraliseringskompleks og fremgangsmåde til dets fremstilling og formulering

Also Published As

Publication number Publication date
TR200002646T2 (tr) 2001-01-22
HUP0101243A1 (hu) 2002-05-29
EP1061803A1 (en) 2000-12-27
IL138345A (en) 2004-12-15
CZ20003288A3 (cs) 2001-03-14
CA2323363C (en) 2008-09-30
CA2323363A1 (en) 1999-09-16
PL192545B1 (pl) 2006-11-30
AU2890999A (en) 1999-09-27
NZ506700A (en) 2003-03-28
EP1061803B1 (en) 2011-05-11
NO20004502L (no) 2000-11-07
EP1061803A4 (en) 2007-12-26
CY1111738T1 (el) 2015-10-07
CN1299235A (zh) 2001-06-13
DK1061803T3 (da) 2011-08-29
NO331207B1 (no) 2011-10-31
HUP0101243A3 (en) 2005-09-28
ZA991922B (en) 1999-09-13
BR9908691A (pt) 2000-12-26
ATE508633T1 (de) 2011-05-15
JP2002506010A (ja) 2002-02-26
ES2366394T3 (es) 2011-10-19
KR20010041796A (ko) 2001-05-25
IL138345A0 (en) 2001-10-31
WO1999045779A1 (en) 1999-09-16
PL343411A1 (en) 2001-08-13
SI1061803T1 (sl) 2011-09-30
CZ303067B6 (cs) 2012-03-21
AU757547B2 (en) 2003-02-27
HU228574B1 (en) 2013-04-29

Similar Documents

Publication Publication Date Title
NO20004502D0 (no) Nye sammensetninger av eprosartan
WO2000004862A3 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
MY127793A (en) Novel form of s-omeprazole.
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
PL363168A1 (pl) Cyklopentanole, kompozycje zawierające takie związki i sposoby leczenia
DE602004030318D1 (de) Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
MY117682A (en) Eprosartan dihydrate and a process for its production and formulation
PL343467A1 (en) Heterocyclically substituted amides, their production and their use
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
MXPA02012244A (es) 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
NO20031033D0 (no) Reseptor i EDb-fibronectindomene
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
DE602004031355D1 (de) Neue 1,3-disubstituierte azetidinderivate zur verwendung als liganden des 5ht2a-rezeptors
BR0315092A (pt) Derivados de piperidina como inibidores de ccr5
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants
BG106154A (en) Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, methods for their production and their use as endothelin receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees